Read by QxMD icon Read

Sripal bangalore

Pedro A Villablanca, Verghese Mathew, Vinod H Thourani, Josep Rodés-Cabau, Sripal Bangalore, Mohammed Makkiya, Peter Vlismas, David F Briceno, David P Slovut, Cynthia C Taub, Patrick M McCarthy, John G Augoustides, Harish Ramakrishna
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has emerged as an alternative to surgical aortic-valve replacement (SAVR) for patients with severe symptomatic aortic stenosis (AS) who are at high operative risk. We sought to determine the long-term (≥1year follow-up) safety and efficacy TAVR compared with SAVR in patients with severe AS. METHODS: A comprehensive search of PubMed, EMBASE, Cochrane Central Register of Controlled Trials, conference proceedings, and relevant Web sites from inception through 10 April 2016...
October 6, 2016: International Journal of Cardiology
Nathaniel R Smilowitz, Navdeep Gupta, Yu Guo, John T Coppola, Sripal Bangalore
OBJECTIVES: Human immunodeficiency virus (HIV) seropositive individuals are predisposed to acute myocardial infarction (AMI). We sought to evaluate management strategies and outcomes of AMI in patients with HIV in the contemporary era. METHODS: We analyzed data from the National Inpatient Sample from 2002 to 2011 for patients admitted with AMI with or without HIV. Propensity-score matching was used to identify HIV seropositive AMI patients with similar characteristics who were managed invasively (cardiac catheterization, percutaneous coronary intervention [PCI], or coronary artery bypass graft surgery [CABG]) or conservatively...
October 2016: Journal of Invasive Cardiology
Sripal Bangalore
No abstract text is available yet for this article.
October 24, 2016: JACC. Cardiovascular Interventions
Chirag Bavishi, Mohammed Ahmed, Vrinda Trivedi, Abdur Rahman Khan, Carlos Gongora, Sripal Bangalore, Franz H Messerli
The comparative efficacy and safety of angiotensin-converting enzyme inhibitors (ACEIs) with other agents in patients ≥65 years of age with cardiovascular diseases or at-risk are unknown. Electronic databases were systematically searched to identify all randomized controlled trials that compared ACEIs with control (placebo or active) and reported long-term cardiovascular outcomes. We required the mean age of patients in the studies to be ≥65 years. Random-effects model was used to pool study results. Sixteen trials with 104,321 patients and a mean follow-up of 2...
August 22, 2016: American Journal of Cardiology
Franz H Messerli, Bora Toklu, Robert Fakheri, Sripal Bangalore
No abstract text is available yet for this article.
August 2016: Annals of Translational Medicine
Sripal Bangalore
No abstract text is available yet for this article.
September 6, 2016: Journal of the American College of Cardiology
Franz H Messerli, Stefano F Rimoldi, Sripal Bangalore
No abstract text is available yet for this article.
October 2016: Journal of Hypertension
Franz H Messerli, Stefano F Rimoldi, Sripal Bangalore, Chirag Bavishi, Stephane Laurent
An elevated resting heart rate has been unequivocally linked to adverse cardiovascular events. Conversely, a physiologically low heart rate may confer longevity benefits. Moreover, pharmacological heart rate lowering reduces cardiovascular outcomes in patients with heart failure, with the magnitude of the reduction associated with survival benefit. In contrast, pharmacological heart rate lowering paradoxically increases cardiovascular events in hypertension, possibly because it elicits a ventricular-vascular mismatch, leading to increased central systolic blood pressure (BP)...
August 16, 2016: Journal of the American College of Cardiology
Alexander Volodarskiy, Sunil Kumar, Shyam Amin, Sripal Bangalore
BACKGROUND: Chronic kidney disease is an independent risk factor for coronary artery disease and is associated with an increase in adverse outcomes. However, the optimal treatment strategies for patients with chronic kidney disease and coronary artery disease are yet to be defined. METHODS: MEDLINE, EMBASE and CENTRAL were searched for studies including at least 100 patients with chronic kidney disease (defined as estimated glomerular filtration rate ≤ 60 mL/min/1...
July 27, 2016: American Journal of Medicine
Sripal Bangalore, Yu Guo, Jinfeng Xu, Saul Blecker, Navdeep Gupta, Frederick Feit, Judith S Hochman
IMPORTANCE: Reduced rates of cardiac catheterization, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) are an unintended consequence of public reporting of cardiogenic shock outcomes in New York. OBJECTIVES: To evaluate whether the referral rates for cardiac catheterization, PCI, or CABG have improved in New York since cardiogenic shock was excluded from public reporting in 2008 and compare them with corresponding rates in Michigan, New Jersey, and California...
September 1, 2016: JAMA Cardiology
Sripal Bangalore, Ajit Bhagwat, Brian Pinto, Praveen K Goel, Prashant Jagtap, Shireesh Sathe, Priyadarshini Arambam, Upendra Kaul
IMPORTANCE: Prior studies have shown that patients with insulin-treated diabetes mellitus (ITDM) have a higher risk of cardiovascular events. However, this finding is controversial, as other studies have shown that the increased risk of cardiovascular events disappears after risk adjustment. In addition, the choice of a drug-eluting stent (limus- vs taxol-eluting) in ITDM is controversial, with studies showing worse outcomes with an everolimus-eluting stent compared with a paclitaxel-eluting stent...
June 1, 2016: JAMA Cardiology
Kevin R Bainey, Robert C Welsh, Bora Toklu, Sripal Bangalore
BACKGROUND: Patients with ST-elevation myocardial infarction (STEMI) and multivessel disease (MVD) most commonly are treated with culprit-only percutaneous coronary intervention (PCI). However, this has been recently challenged, suggesting benefit with complete revascularization (CR). Still, these latest findings are largely based on clinical trials powered for composite outcomes that frequently include "softer" end points. We performed a meta-analysis comparing routine culprit-only PCI vs CR in STEMI, with an emphasis on "hard" clinical end points...
March 10, 2016: Canadian Journal of Cardiology
Christina M Wyatt, Matthew Shineski, Glenn M Chertow, Sripal Bangalore
Despite the high cardiovascular risk associated with chronic kidney disease, a recent systematic review confirmed that patients with kidney disease remain underrepresented in cardiovascular trials. Two ongoing trials are assessing the risk:benefit of aggressive evaluation and intervention for ischemic heart disease in patients with advanced chronic kidney disease.
June 2016: Kidney International
Franz H Messerli, Sripal Bangalore
No abstract text is available yet for this article.
August 2016: American Journal of Medicine
Sripal Bangalore, Yu Guo, Zaza Samadashvili, Saul Blecker, Edward L Hannan
BACKGROUND: Guidelines recommend coronary artery bypass graft surgery (CABG) over percutaneous coronary intervention (PCI) for multivessel disease and severe left ventricular systolic dysfunction. However, CABG has not been compared with PCI in such patients in randomized trials. METHODS AND RESULTS: Patients with multivessel disease and severe left ventricular systolic dysfunction (ejection fraction ≤35%) who underwent either PCI with everolimus-eluting stent or CABG were selected from the New York State registries...
May 31, 2016: Circulation
Pawan Hari, Ajay J Kirtane, Sripal Bangalore
Retrograde approach to chronic total occlusions (CTO) has been described via saphenous vein grafts, septal and epicardial collaterals. We report for the first time a successful retrograde approach to an ostial left anterior descending (LAD) artery CTO through a failed left internal mammary artery (LIMA) to LAD anastamosis. This case demonstrates the technical aspects of using a LIMA conduit as a retrograde approach to CTO. © 2015 Wiley Periodicals, Inc.
May 2016: Catheterization and Cardiovascular Interventions
Franz Messerli, Sripal Bangalore, Bernhard Meier
No abstract text is available yet for this article.
November 1, 2015: European Heart Journal
Mina Owlia, Sripal Bangalore
No abstract text is available yet for this article.
August 2016: Canadian Journal of Cardiology
Sripal Bangalore, Bora Toklu, Deepak L Bhatt
BACKGROUND: Bioresorbable vascular scaffolds (BVS) have been shown to be non-inferior to second generation drug eluting stents in recent clinical trials. However, the trials were not powered for individual endpoints and there is concern for increased device thrombosis with BVS. METHODS: We performed a systematic search for randomized clinical trials of BVS versus EES. Efficacy outcomes were target lesion revascularization (TLR) and target vessel revascularization (TVR)...
June 1, 2016: International Journal of Cardiology
David D Waters, Priscilla Y Hsue, Sripal Bangalore
No abstract text is available yet for this article.
April 19, 2016: JAMA: the Journal of the American Medical Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"